Pacific Edge reports slight dip in cancer test volumes

Cancer diagnostics company, Pacific Edge, has reported a slight decrease in test volumes for the second quarter of the 2025 financial year.

The company said tests processed at its laboratories in the three months to the end of September 2024 were lower than the previous quarter.

However, it highlighted strong demand from its US customer, Kaiser Permanente, and a lift in volume in the Asia-Pacific region, which helped mitigate the impact of the challenges faced by the sales team.

Total laboratory throughput in the second quarter fell 2% to 7,045 tests.

US test volumes were down 3.8% to 5,682 tests.

On the other hand, Asia-Pacific volumes were up 6.2% to 1,363 tests.

The company attributed the decline in test volumes for the first half of the 2025 financial year to a reorganisation it undertook to reduce the size of the sales team.